Stimulant Dispensing to Children Decreased After Start of Pandemic, During Shortage
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 27, 2025 -- Stimulant dispensing to children aged 5 to 17 years decreased after the start of the COVID-19 pandemic and during a shortage of immediate-release mixed amphetamine salts in October 2022, according to a study published online Jan. 27 in Pediatrics.
Sijia He, from the University of Michigan Medical School in Ann Arbor, and colleagues analyzed the 2017 to 2023 IQVIA Longitudinal Prescription Database, which captures 92 percent of U.S. prescriptions, to assess changes in prescription stimulant dispensing to children aged 5 to 17 years. The level and slope changes in the monthly stimulant dispensing rate were evaluated in March 2020 and October 2022.
The researchers found that the monthly stimulant dispensing rate to children changed by −454.9 children per 100,000 in March 2020, representing an 18.8 percent decrease relative to January 2017. This rate increased to 12.7 children per 100,000 per month after March 2020. No level change or slope change was seen in October 2022, although the estimates were negative (−39.7 children per 100,000 and −12.1 children per 100,000 per month, respectively). During October 2022, a level decrease was seen in the monthly dispensing rate for immediate-release mixed amphetamine salts, while a level increase was seen in the monthly dispensing rate for dexmethylphenidate.
“Our findings indirectly demonstrate how increased demand for a medication class in adults may adversely affect access to these treatments for children,” coauthor Kao-Ping Chua, M.D., Ph.D., of the University of Michigan C.S. Mott Children's Hospital and Susan B. Meister Child Health Evaluation and Research Center in Ann Arbor, said in a press release. “It’s crucial to address the shortage of stimulant medications because so many kids rely on them. Untreated ADHD (attention-deficit/hyperactivity disorder) symptoms can harm children’s health and learning.”
One author disclosed receipt of consulting fees from Greylock McKinnon Associates.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Further Support and Information on COVID-19
Read this next
Hospital-Onset Antimicrobial Resistant Infections Increased During COVID-19 Pandemic
MONDAY, May 5, 2025 -- Hospital-onset antimicrobial-resistant infections increased across U.S. hospitals during and beyond the COVID-19 pandemic, according to a study published...
Prevalence of Most Cancer Risk Factors Unchanged Before, After Pandemic
THURSDAY, April 24, 2025 -- Smoking rates continued to decline during the COVID-19 pandemic, but other major risk factors for cancer remained stable, according to a study...
Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate
MONDAY, April 21, 2025 -- Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.